Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Discovery

• Publication date

  2017-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-17-0222PMID 28652380PMCID PMC5628128
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequence Analysis

  2020cited by this paper
• Systemic Immunity Is Required for Effective Cancer Immunotherapy.

  2017cited by this paper
• The immune microenvironment of breast ductal carcinoma in situ

  2016cited by this paper
• Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

  2016cited by this paper
• Coinhibitory Pathways in Immunotherapy for Cancer.

  2016cited by this paper
• The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ

  2016cited by this paper
• Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention

  2016cited by this paper
• Compendium of Immune Signatures Identifies Conserved and Species-Specific Biology in Response to Inflammation.

  2016influential reference
• A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells.

  2016cited by this paper
• Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

  2016cited by this paper
• The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.

  2016cited by this paper
• Clinical relevance of host immunity in breast cancer: from TILs to the clinic

  2016influential reference
• Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer.

  2016cited by this paper
• Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

  2016cited by this paper
• Robust enumeration of cell subsets from tissue expression profiles

  2015influential reference
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

  2015cited by this paper
• A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.

  2015cited by this paper
• IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis

  2015cited by this paper
• Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers

  2015cited by this paper
• TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

  2015cited by this paper
• MiXCR: software for comprehensive adaptive immunity profiling

  2015cited by this paper
• limma powers differential expression analyses for RNA-sequencing and microarray studies

  2015cited by this paper
• Differential immune cell densities in ductal carcinoma In-Situ and invasive breast cancer: Possible role of leukocytes in early stages of carcinogenesis

  2015cited by this paper
• The role of the microbiota in inflammation, carcinogenesis, and cancer therapy

  2015cited by this paper
• ImmPort: disseminating data to the public for the future of immunology

  2014cited by this paper
• HTSeq—a Python framework to work with high-throughput sequencing data

  2014cited by this paper
• Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

  2014cited by this paper
• Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

  2014cited by this paper
• FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• STAR: ultrafast universal RNA-seq aligner

  2013cited by this paper
• Inferring tumour purity and stromal and immune cell admixture from expression data

  2013cited by this paper
• CD8+ TCR Repertoire Formation Is Guided Primarily by the Peptide Component of the Antigenic Complex

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Two methods for full-length RNA sequencing for low quantities of cells and single cells

  2012cited by this paper
• Palindromic Nucleotide Analysis in Human T Cell Receptor Rearrangements

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast Cancer

  2012cited by this paper
• Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling

  2011cited by this paper
• Leukocyte composition of human breast cancer

  2011cited by this paper
• Allele-specific copy number analysis of tumors

  2010cited by this paper
• CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

  2009cited by this paper
• edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

  2009cited by this paper
• Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast

  2008cited by this paper
• Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution

  2008cited by this paper
• Genome-wide functional synergy between amplified and mutated genes in human breast cancer.

  2008cited by this paper
• Microenvironment of the Involuting Mammary Gland Mediates Mammary Cancer Progression

  2007cited by this paper
• Molecular definition of breast tumor heterogeneity.

  2007cited by this paper
• Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

  2006cited by this paper
• Paradoxical roles of the immune system during cancer development

  2006cited by this paper
• A Mathematical Theory of Communication

  2006influential reference
• spatstat: An R Package for Analyzing Spatial Point Patterns

  2005cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005influential reference
• Generalized Linear Mixed Models

  2005cited by this paper
• The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis.

  2004cited by this paper
• Methods for Analysing Spatial Processes of Several Types of Points

  1982cited by this paper
• A new look at the statistical model identification

  1974cited by this paper
• Bioinformatics Applications Note Systems Biology Htsanalyzer: an R/bioconductor Package for Integrated Network Analysis of High-throughput Screens

  year unknowncited by this paper

• CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer

  2026influential citation
• Prognostic Significance of CD4+ T Cell Transcription Factors in Tumor Microenvironment: Insights from Tumor-Infiltrating Lymphocytes in Breast Cancer.

  2026cites this paper
• The impact of immune microenvironment on local control of ductal carcinoma in situ receiving breast conservative therapy

  2026cites this paper
• Roles of Neutrophils in Autoimmune Diseases and Cancers

  2025cites this paper
• Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial

  2025cites this paper
• Decoding the spatial dynamics of tumor and immune cell interactions in solid cancers.

  2025cites this paper
• Celastrol-loaded ginsenoside Rg3 liposomes enhance anti-programmed death ligand 1 immunotherapy by inducing immunogenic cell death in triple-negative breast cancer.

  2025cites this paper
• CXCR4+ mammary gland macrophageal niche promotes tumor initiating cell activity and immune suppression during tumorigenesis

  2025cites this paper
• Prognostic value of circadian rhythm-associated genes in breast cancer

  2025cites this paper
• Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights

  2025cites this paper
• Spatial proteomics and transcriptomics reveal early immune cell organization in pancreatic intraepithelial neoplasia

  2025cites this paper
• DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges

  2025influential citation
• Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic

  2025cites this paper
• SpatialKNifeY (SKNY): Extending from spatial domain to surrounding area to identify microenvironment features with single-cell spatial omics data

  2025cites this paper
• Complex rearrangements fuel ER+ and HER2+ breast tumours

  2025cites this paper
• Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells

  2025cites this paper
• Elevated Siglec-7 expression correlates with adverse clinicopathological, immunological, and therapeutic response signatures in breast cancer patients

  2025cites this paper
• Immunoprevention of non-viral cancers: challenges and strategies for early intervention

  2025cites this paper
• Immunohistochemical Study of IL-6 and IL-10 Expression in Breast Cancer Correlations with ER, PR, Her-2, Ki-67, and Clinicopathological Features in Iraqi Women

  2025cites this paper
• Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities.

  2025cites this paper
• CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma

  2025cites this paper
• T-helper Transcription Factor Profiling in Peripheral Blood Mononuclear Cells: A Non-invasive Approach to Predicting Disease Stage in Breast Cancer.

  2025cites this paper
• Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization

  2025cites this paper
• Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer.

  2025cites this paper
• Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers

  2025cites this paper
• Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment

  2025cites this paper
• Biomarkers Predicting Progression and Prognosis of Ductal Carcinoma In Situ (DCIS)

  2025cites this paper
• Circulating CD3 + CD8 + T Lymphocytes as Indicators of Disease Status in Patients With Early Breast Cancer

  2025cites this paper
• Advances and challenges in cancer immunoprevention and immune interception

  2024cites this paper
• Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer

  2024cites this paper
• Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma

  2024cites this paper
• Deciphering normal and cancer stem cell niches by spatial transcriptomics: opportunities and challenges

  2024cites this paper
• Different oncogenes and reproductive histories shape the progression of distinct premalignant clones in multistage mouse breast cancer models.

  2024cites this paper
• Precise HER2 Protein Degradation via Peptide‐Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy

  2024cites this paper
• Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV) status

  2024cites this paper
• Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

  2024cites this paper
• Estrogen receptor regulation of the Immune Microenvironment in Breast Cancer.

  2024cites this paper
• Vaccines for cancer prevention: exploring opportunities and navigating challenges

  2024cites this paper
• Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

  2024cites this paper
• Severe degranulation of mesenteric mast cells in an experimental rat mammary tumor model

  2024cites this paper
• Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast

  2024cites this paper
• Functional and clinical roles of stromal PDGF receptors in tumor biology

  2024cites this paper
• Detecting cell types and densities in the tumor microenvironment improves prognostic risk assessment for breast cancer

  2024cites this paper
• Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets

  2024cites this paper
• Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert “Cold” Tumors to “Hot” Tumors

  2024cites this paper
• Pooled genetic screens identify breast cancer risk genes involved in evasion from T cell-mediated killing

  2024influential citation
• Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer

  2024cites this paper
• Towards targeting the breast cancer immune microenvironment

  2024cites this paper
• Cell-cell interactions mediating primary and metastatic breast cancer dormancy

  2024cites this paper
• Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.

  2024cites this paper
• Analysis of the relationship between resistin with prognosis, cell migration, and p38 and ERK1/2 activation in breast cancer.

  2024cites this paper
• Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.

  2024cites this paper
• Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity

  2024cites this paper
• Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer

  2024cites this paper
• Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers

  2024cites this paper
• Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study

  2024cites this paper
• Cold-Inducible RNA Binding Protein Impedes Breast Tumor Growth in the PyMT Murine Model for Breast Cancer

  2024cites this paper
• HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

  2024cites this paper
• Single-cell transcriptome analysis reveals immune microenvironment changes and insights into the transition from DCIS to IDC with associated prognostic genes

  2024cites this paper
• Nonlinear progression during the occult transition establishes cancer lethality

  2024cites this paper
• Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets

  2024cites this paper
• Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics

  2024cites this paper
• Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance

  2024cites this paper
• Clonal evolution in healthy and premalignant tissues: implications for early cancer interception strategies

  2023cites this paper
• PARP9 knockdown confers protection against chemoresistance and immune escape of breast cancer cells by blocking the PI3K/AKT pathway

  2023cites this paper
• High expression of RTN4IP1 predicts adverse prognosis for patients with breast cancer

  2023cites this paper
• SLC35A2 expression drives breast cancer progression via ERK pathway activation

  2023cites this paper
• Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer

  2023cites this paper
• Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development.

  2023cites this paper
• Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells

  2023cites this paper
• Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention.

  2023cites this paper
• Human Ductal Carcinoma In Situ: Advances and Future Perspectives.

  2023cites this paper
• The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.

  2023cites this paper
• Association of Enolase-1 with Prognosis and Immune Infiltration in Breast Cancer by Clinical Stage

  2023cites this paper
• Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters

  2023cites this paper
• Everybody needs good neighbours: the progressive DCIS microenvironment.

  2023cites this paper
• Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression

  2023cites this paper
• Heterogeneity and transcriptional drivers of triple-negative breast cancer

  2023cites this paper
• A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.

  2023cites this paper
• Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers

  2023cites this paper
• SILAC proteomics based on 3D cell spheroids unveils the role of RAC2 in regulating the crosstalk between triple-negative breast cancer cells and tumor-associated macrophages.

  2023cites this paper
• Elevated profiles of peripheral Th22, Th17, Th2 cells, and decreased percentage of Th1 cells in breast cancer patients

  2023cites this paper
• Research Status of Immune Microenvironment in Triple Negative Breast Cancer

  2023cites this paper
• The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer

  2023cites this paper
• Expression and Clinical Significance of TIGIT in Primary Breast Cancer

  2023cites this paper
• Isogenic Mammary Models of Intraductal Carcinoma Reveal Progression to Invasiveness in the Absence of a Non-Obligatory In Situ Stage

  2023cites this paper
• Regional variation in the tumor microenvironment, immune escape and prognostic factors in breast cancer in sub-Saharan Africa.

  2023cites this paper
• Spatial Biology of Breast Cancer.

  2023cites this paper
• A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression

  2023influential citation
• Breast Cancer Immunity: It is TIME for the Next Chapter.

  2023cites this paper
• Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers.

  2023cites this paper
• Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.

  2023cites this paper
• Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy

  2022cites this paper
• Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression

  2022cites this paper
• MALINC1 an Immune-Related Long Non-Coding RNA Associated with Early-Stage Breast Cancer Progression

  2022cites this paper
• A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

  2022cites this paper
• Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer

  2022cites this paper
• Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study

  2022cites this paper
• The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ

  2022cites this paper
• Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2

  2022influential citation